Breaking News, Collaborations & Alliances

Sangamo BioSciences, CIRM In Strategic Pact

To develop ZFP therapeutic for blood disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sangamo BioSciences has received a $6.4 million Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to use its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem cells (HSCs) to develop a potential ZFP Therapeutic for beta-thalassemia.   The four-year grant provides matching funds for preclinical work to support an IND application and a Phase I trial in transfusion-dependent beta-thalassemia, a genetic blood disease caused by mutations in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters